Candidate drug that boosts protective brain protein in mice has potential to treat Alzheimer's disease

Studies indicate that Alzheimer's will be the third most common cause of death in 2030. Paola Barbarino, chairman of "Alzheimer"s Disease International, explains the reasons.

Candidate drug that boosts protective brain protein in mice has potential to treat Alzheimer's disease

As researchers work to improve treatment of Alzheimer's disease, new research by UCLA Health identified a candidate drug that reduces levels of a toxic form of a protein in the brain caused by the disease and improved memory in mice by boosting production of a protective protein.

Alzheimer Europe | World Health Assembly approves six-year extension to the Global Action Plan on the Public Health Response to Dementia

On 23 May 2025, during the 78th World Health Assembly in Geneva (Switzerland), a six-year extension to the Global Action Plan on the Public Health Response to Dementia was adopt

Researchers discover molecule that reverses cognitive deficits associated with dementia and aging

Dementia affects millions globally, impacting memory, reasoning, and everyday activities. As the population ages, understanding and addressing cognitive decline becomes increasingly critical. Alzheimer’s disease, the most common form of dementia, affects around 50 million people worldwide. This number is projected to triple to over 150 million by 2050, especially burdening low-income and middle-income countries. Globally, dementia care costs nea…

Researchers have shown that increasing hevin levels in the brain increases the quality of their neural connections and can reverse their aging Brazilian researchers have identified a molecule capable of reversing cognitive deficits associated with aging and dementia in their animal tests. The team has shown that increasing the levels of this molecule, known as hevina, increases the connections between neurons (sinapsis) in older rodents and anim…

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition […]